Disease burden of non-Hodgkin's lymphoma in Jiangsu Province, 1990-2019
LIU Fu-dong1, LI Xian-peng2, XU Xiao-qing1, YU Hao3, LUO Peng-fei3, ZHOU Jin-yi3
1. Yancheng Municipal Center for Disease Control and Prevention, Yancheng, Jiangsu 224002, China; 2. Fushan District Center for Disease Control and Prevention, Yantai, Shandong 265500, China; 3. Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu 210000, China
Abstract：Objective To analyze the changes in disease burden of non-Hodgkin's lymphoma in Jiangsu Province from 1990 to 2019, and to provide a scientific basis for prevention and control of non-Hodgkin's lymphoma. Methods We analyzed the gender, age distribution and changing trends of non-Hodgkin's lymphoma in Jiangsu Province during 1990-2019 based on the case number, incidence, mortality, disability-adjusted life years (DALYs), and DALYs rate of non-Hodgkin's lymphoma in Jiangsu Province extracted from the database of the Global Burden of Disease Study 2019. Results In 2019, the number of non-Hodgkin's lymphoma cases in Jiangsu Province was 7,299, and the standardized incidence rate was 5.92/100,000. The number of deaths was 3,182, and the standardized mortality rate 2.45/100,000. The DALYs was 85,328 person-years, and the standardized DALYs rate 71.79/100,000. Compared with those in 1990, all indicators showed an upward trend. The age-specific morbidity, mortality and DALYs rate of non-Hodgkin's lymphoma in different gender populations all increased with age, but the morbidity, mortality and DALYs rate were higher in males than in females, showing statistically significant differences (P<0.05). Conclusion The disease burden of non-Hodgkin's lymphoma in Jiangsu Province from 1990 to 2019 showed an increasing trend, and males and the elderly were the high-risk groups of its disease burden. Comprehensive prevention and control measures against non-Hodgkin's lymphoma should be formulated to reduce disease burden of the patients.
[1] Dereje N. Global burden of 369 diseases and injuries in 204 countries and territories, 1990—2019:a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258):1204-1222. [2] 石远凯,孙燕,刘彤华.中国恶性淋巴瘤诊疗规范(2015年版)[J].中华肿瘤杂志, 2015, 37(2):148-158. [3] 庹吉妤,张敏,郑荣寿,等.2015年中国恶性淋巴瘤发病与死亡分析[J].中国肿瘤, 2021, 30(1):35-40. [4] Liu W, Liu J, Song Y, et al. Burden of lymphoma in China,2006-2016: an analysis of the Global Burden of Disease Study 2016[J]. J Hematol Oncol, 2019, 12(1):1-9. [5] 王芳旭,陶立波,董咚,等.中国霍奇金淋巴瘤患者疾病负担调查-基于一项在线问卷调查的研究[J].中国医疗保险, 2020,(1):60-64. [6] 赵敏,陈婷,黄振光,等.1990—2019年中国痛风疾病负担研究[J].现代预防医学, 2021, 48(21):3974-3978. [7] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J].Blood, 2016, 127(20):2375-2390. [8] Thyss A, Saada E, Gastaud L, et al. Hodgkin's lymphoma in older patients: an orphan disease?[J]. Mediterr J Hematol Infect Dis, 2014, 6(1):e2014050. [9] Maggioncalda A, Malik N, Shenoy P, et al. Clinical, molecular, and environmental risk factors for Hodgkin lymphoma[J]. Adv Hematol, 2011:736261. [10] Islami F,Chen W,Yu XQ,et al. Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013[J]. Ann Oncol, 2017, 28(10):2567-2574. [11] 丁贤彬,焦艳,毛德强,等.2016年重庆市恶性肿瘤早死概率及疾病负担分析[J].实用预防医学,2019, 26(2):153-155.
2023, Vol. 30 
